Publications
331 results found
Sellar GC, Li L, Watt KP, et al., 2001, BARX2 induces cadherin 6 expression and is a functional suppressor of ovarian cancer progression, CANCER RESEARCH, Vol: 61, Pages: 6977-6981, ISSN: 0008-5472
- Author Web Link
- Cite
- Citations: 52
Paige AJW, Taylor KJ, Taylor C, et al., 2001, <i>WWOX</i>:: A candidate tumor suppressor gene involved in multiple tumor types, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, Vol: 98, Pages: 11417-11422, ISSN: 0027-8424
- Author Web Link
- Cite
- Citations: 199
Clark TG, Stewart ME, Altman DG, et al., 2001, A prognostic model for ovarian cancer, British Journal of Cancer, Vol: 85, Pages: 944-952, ISSN: 0007-0920
Watt KP, Li L, Seller GC, et al., 2001, Loss of heterozygosity on chromosome 11Q24 in colorectal and epithelial ovarian cancer., BRITISH JOURNAL OF CANCER, Vol: 85, Pages: 73-73, ISSN: 0007-0920
Stronach EA, Sellar GC, Blenkiron C, et al., 2001, Identification of putative ovarian cancer tumour suppressor genes from chromosome (chr) 11 by expression difference analysis, BRITISH JOURNAL OF CANCER, Vol: 85, Pages: 73-73, ISSN: 0007-0920
Blenkiron C, Sellar GC, Stronach E, et al., 2001, Functional identification of RALDH2 dysregulation by cDNA representational difference analysis in chromosome 11 mediated growth suppression of ovarian cancer., BRITISH JOURNAL OF CANCER, Vol: 85, Pages: 73-73, ISSN: 0007-0920
Gourley C, Gabra H, 2001, Immunological and gene therapy for ovarian cancer a technical overview., Methods Mol Med, Vol: 39, Pages: 713-728, ISSN: 1543-1894
Conventional medical approaches are limited in part on the prognosis of ovarian cancer. Although the advent of platinum- and taxane-based combination chemotherapy represents a significant advance in the treatment of ovarian carcinoma, the 5-yr survival of patients with intraperitoneal (ip) disseminated disease remains poor at only 30-40% (1-3). The vast majority of patients present with disease that is advanced because of transcoelomic spread yet remains locoregionally contained, rather than truly metastatic to distant sites by blood or lymphatic spread.
Gabra H, Sellar G, Li L, et al., 2000, BARX2: A tumour progression-suppressor and modulator of cisplatin resistance in ovarian cancer?, BRITISH JOURNAL OF CANCER, Vol: 83, Pages: 24-24, ISSN: 0007-0920
Paige AJW, Taylor KJ, Stewart A, et al., 2000, A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D, CANCER RESEARCH, Vol: 60, Pages: 1690-1697, ISSN: 0008-5472
- Author Web Link
- Cite
- Citations: 91
Vitale G, Pellizzari R, Recchi C, et al., 1999, Anthrax lethal factor cleaves the N-terminus of MAPKKS and induces tyrosine/threonine phosphorylation of MAPKS in cultured macrophages, JOURNAL OF APPLIED MICROBIOLOGY, Vol: 87, Pages: 288-288, ISSN: 1364-5072
- Author Web Link
- Cite
- Citations: 45
Milner BJ, Brown I, Gabra H, et al., 1999, A protective role for common <i>p21<SUP>WAF1/Cip1</SUP></i> polymorphisms in human ovarian cancer, INTERNATIONAL JOURNAL OF ONCOLOGY, Vol: 15, Pages: 117-119, ISSN: 1019-6439
- Author Web Link
- Cite
- Citations: 8
Macleod KG, Gilmour LMR, Sellar GC, et al., 1999, Differential signalling in response to TGF-α and neuregulins in ovarian cancer after treatment with cisplatin and elucidation of changed gene expression, BRITISH JOURNAL OF CANCER, Vol: 80, Pages: 85-85, ISSN: 0007-0920
Taylor KJ, Gabra H, Sgouros J, et al., 1999, A homozygous deletion of 16q23 associated with multiple cancers, BRITISH JOURNAL OF CANCER, Vol: 80, Pages: 29-29, ISSN: 0007-0920
Sellar GC, Rabiasz GJ, Miller EP, et al., 1999, Identification of putative chromosome (Chr) 11 ovarian cancer tumor suppressor genes: A comparison of three difference analysis methodologies., BRITISH JOURNAL OF CANCER, Vol: 80, Pages: 29-29, ISSN: 0007-0920
Connolly KC, Gabra H, Millwater CJ, et al., 1999, Identification of a region of frequent loss of heterozygosity at 11q24 in colorectal cancer, CANCER RESEARCH, Vol: 59, Pages: 2806-2809, ISSN: 0008-5472
- Author Web Link
- Cite
- Citations: 31
Watson JEV, Gabra H, Taylor KJ, et al., 1999, Identification and characterization of a homozygous deletion found in ovarian ascites by representational difference analysis, GENOME RESEARCH, Vol: 9, Pages: 226-233, ISSN: 1088-9051
- Author Web Link
- Cite
- Citations: 8
Langdon SP, Gabra H, Bartlett JMS, et al., 1998, Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogen, CLINICAL CANCER RESEARCH, Vol: 4, Pages: 2245-2251, ISSN: 1078-0432
- Author Web Link
- Cite
- Citations: 38
Vitale G, Pellizzari R, Recchi C, et al., 1998, Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol: 248, Pages: 706-711, ISSN: 0006-291X
- Author Web Link
- Cite
- Citations: 350
Bertelli G, Gabra H, Craig J, et al., 1998, Clinical factors predicting for durable disease-free survival in a study of dose intensive therapy for stage 4 breast cancer, BONE MARROW TRANSPLANTATION, Vol: 21, Pages: S56-S56, ISSN: 0268-3369
Sellar GC, Rabiasz GJ, Li L, et al., 1998, Functional analysis of novel ovarian cancer suppressor regions on chromosome 11., BRITISH JOURNAL OF CANCER, Vol: 78, Pages: 71-71, ISSN: 0007-0920
Cameron DA, Craig J, Gabra H, et al., 1996, High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer - A phase I/II study, BRITISH JOURNAL OF CANCER, Vol: 74, Pages: 2013-2017, ISSN: 0007-0920
- Author Web Link
- Cite
- Citations: 7
Gabra H, Cameron DA, Lee LE, et al., 1996, Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer, BRITISH JOURNAL OF CANCER, Vol: 74, Pages: 2008-2012, ISSN: 0007-0920
- Author Web Link
- Cite
- Citations: 23
Cameron DA, Craig J, Gabra H, et al., 1996, High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer--phase I/II study. Edinburgh Breast Group., Br J Cancer, Vol: 74, Pages: 2013-2017, ISSN: 0007-0920
Current treatments for metastatic breast cancer are not associated with significant survival benefits despite response rates of over 50%. High-dose therapy with autologous bone marrow transplantation (ABMT) has been investigated, particularly in North America, and prolonged survival in up to 25% of women has been reported, but with a significant treatment-related mortality. However, in patients with haematological malignancies undergoing autologous transplantation, haematopoietic reconstruction is significantly quicker and mortality lower than with ABMT, when peripheral blood progenitor cells (PBPCs) are used. In 32 women with metastatic breast cancer, we investigated the feasibility of PBPC mobilisation with high-dose cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) after 12 weeks' infusional induction chemotherapy and the subsequent efficacy of the haematopoietic reconstitution after conditioning with melphalan and either etoposide or thiotepa. PBPC mobilisation was successful in 28/32 (88%) patients, and there was a rapid post-transplantation haematopoietic recovery: median time to neutrophils > 0.5 x 10(9) l-1 was 14 days and to platelets > 20 x 10(9) l-1 was 10 days. There was no procedure-related mortality, and the major morbidity was mucositis (WHO grade 3-4) in 18/32 patients (56%). In a patient group of which the majority had very poor prognostic features, the median survival from start of induction chemotherapy was 15 months. Thus, PBPC mobilisation and support of high-dose chemotherapy is feasible after infusional induction chemotherapy for patients with metastatic breast cancer, although the optimum drug combination has not yet been determined.
Gabra H, Watson JEV, Taylor KJ, et al., 1996, Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis, CANCER RESEARCH, Vol: 56, Pages: 950-954, ISSN: 0008-5472
- Author Web Link
- Cite
- Citations: 109
Gabra H, Watson JEV, Eccles DM, et al., 1996, A statistical analysis of chromosome 11 and 17 loss of heterozygosity in epithelial ovarian cancer, INTERNATIONAL JOURNAL OF ONCOLOGY, Vol: 8, Pages: 625-631, ISSN: 1019-6439
- Author Web Link
- Cite
- Citations: 1
Devlin J, Elder PA, Gabra H, et al., 1996, High frequency of chromosome 9 deletion in ovarian cancer: Evidence for three tumour-suppressor loci, BRITISH JOURNAL OF CANCER, Vol: 73, Pages: 420-423, ISSN: 0007-0920
- Author Web Link
- Cite
- Citations: 45
Gabra H, Langdon SP, Watson JEV, et al., 1995, Loss of heterozygosity at 11q22 correlates with low progesterone receptor content in epithelial ovarian cancer, CLINICAL CANCER RESEARCH, Vol: 1, Pages: 945-953, ISSN: 1078-0432
- Author Web Link
- Cite
- Citations: 16
GABRA H, TAYLOR L, COHEN BB, et al., 1995, CHROMOSOME-11 ALLELE IMBALANCE AND CLINICOPATHOLOGICAL CORRELATES IN OVARIAN-TUMORS, BRITISH JOURNAL OF CANCER, Vol: 72, Pages: 367-375, ISSN: 0007-0920
- Author Web Link
- Cite
- Citations: 48
CAMERON DA, GABRA H, LEONARD RCF, 1994, CONTINUOUS 5-FLUOROURACIL IN THE TREATMENT OF BREAST-CANCER, BRITISH JOURNAL OF CANCER, Vol: 70, Pages: 120-124, ISSN: 0007-0920
- Author Web Link
- Cite
- Citations: 81
SIKORA K, CHAN S, EVAN G, et al., 1987, C-MYC ONCOGENE EXPRESSION IN COLORECTAL-CANCER, CANCER, Vol: 59, Pages: 1289-1295, ISSN: 0008-543X
- Author Web Link
- Cite
- Citations: 187
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.